Most recently, attention has fallen on immune checkpoint inhibitors (ICIs), IL-13Rα2-targeting, and other forms of precision therapy aimed at a more tailored approach in the treatment of ACC. The gene discussed is IL13RA2; the disease is adrenal cortex carcinoma.